Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced a new partnership with New York Jets running back Tevin
Coleman and his wife, Akilah, whose 4-year-old daughter lives with
sickle cell disease (SCD), with the goal of educating, inspiring,
and raising awareness about SCD – especially among other parents
and caregivers. Starting today, just ahead of World Sickle Cell Day
on June 19, 2022, which also happens to be Father’s Day, the
Colemans will be sharing their family’s story as part of Sickle
Cell Speaks, GBT’s education campaign that highlights authentic
stories of those living with sickle cell to raise awareness and
dispel misconceptions about the disease.
“As a dad and husband, there’s nothing more important than the
health of my family. This World Sickle Cell Day and Father’s Day, I
am especially grateful for my daughter, Nazaneen, who lives and
thrives with sickle cell disease,” said Tevin Coleman, New York
Jets running back and sickle cell dad. “Too many children and
adults with sickle cell go untreated, don’t have regular checkups,
and only get care when they suffer from symptoms. By sharing our
family’s story, we hope to inspire other families and warriors
through their journeys to learn all they can and get the early and
proactive care that’s best for them.”
Tevin and Akilah will share their playbook for families impacted
by sickle cell via media opportunities, in-person appearances,
social media, and sickle cell community engagement. To learn more,
follow Tevin Coleman on Twitter and Instagram, Akilah Coleman on
Twitter and Instagram, and Sickle Cell Speaks on Instagram and
Facebook.
“We are excited to partner with Tevin Coleman and his wonderful
family to shine the light on their story as we join the sickle cell
community in recognizing World Sickle Cell Day,” said Kim
Smith-Whitley, M.D., executive vice president and head of research
and development of GBT and a pediatric hematologist caring for SCD
patients for more than 30 years. “The Colemans have taken important
steps to build a foundation of healthy habits and support for their
daughter that we hope will help other families create their own
playbook for tackling sickle cell, along with the resources
available on Sickle Cell Speaks.”
About Sickle Cell DiseaseSickle cell disease
(SCD) affects more than 100,000 people in the United States,1 an
estimated 52,000 people in Europe,2 and millions of people
throughout the world, particularly among those whose ancestors are
from sub-Saharan Africa.3 It also affects people of Hispanic, South
Asian, Southern European and Middle Eastern ancestry.4 SCD is a
lifelong inherited rare blood disorder that impacts hemoglobin, a
protein carried by red blood cells that delivers oxygen to tissues
and organs throughout the body.4 Due to a genetic mutation,
individuals with SCD form abnormal hemoglobin known as sickle
hemoglobin. When sickle hemoglobin becomes deoxygenated, it
polymerizes to form rods, which deforms the red blood cells into
sickled – crescent-shaped, rigid – cells.4,5,6 The recurrent
sickling process causes destruction of the red blood cells and
hemolytic anemia (low hemoglobin due to red blood cell destruction)
and blockages in capillaries and small blood vessels
(vaso-occlusion), which impede the flow of blood and oxygen
delivery throughout the body, commonly referred to as
vaso-occlusive crises (VOCs). The diminished oxygen delivery to
tissues and organs can lead to life-threatening complications,
including stroke and irreversible organ damage.5,6,7,8
Complications of SCD can begin in early childhood and can include
neurocognitive impairment, acute chest syndrome, and silent and
overt stroke, among other serious issues.9 Approximately 16,000 of
those affected by SCD in the U.S. are children ages 4 to 11 years
old.10 Early intervention and treatment of SCD have shown potential
to modify the course of this disease, reduce symptoms and events,
prevent long-term organ damage, and extend life expectancy.5
About Global Blood TherapeuticsGlobal
Blood Therapeutics (GBT) is a biopharmaceutical company
dedicated to the discovery, development and delivery of
life-changing treatments that provide hope to underserved patient
communities, starting with sickle cell disease (SCD). Founded in
2011, GBT is delivering on its goal to transform the treatment and
care of SCD, a lifelong, devastating inherited blood disorder. The
company has introduced Oxbryta® (voxelotor), the first
FDA-approved medicine that directly inhibits sickle hemoglobin
(HbS) polymerization, the root cause of red blood cell sickling in
SCD. GBT is also advancing its pipeline program in SCD with
inclacumab, a P-selectin inhibitor in Phase 3 development to
address pain crises associated with the disease, and GBT021601
(GBT601), the company’s next generation HbS polymerization
inhibitor. In addition, GBT’s drug discovery teams are working on
new targets to develop the next generation of treatments for SCD.
To learn more, please visit www.gbt.com and follow the company
on Twitter @GBT_news.
Forward-Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements containing the words “will,” “anticipates,” “plans,”
“believes,” “forecast,” “estimates,” “expects” and “intends,” or
similar expressions. These forward-looking statements are based on
GBT’s current expectations and actual results could differ
materially. Statements in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. GBT intends these forward-looking statements, including
statements regarding GBT’s priorities, dedication, commitment,
focus, goals, mission, vision and positioning; the partnership with
Mr. Coleman and his family and related activities and expectations;
safety, efficacy and mechanism of action of Oxbryta and other
product characteristics; impacting the treatment, course and care
of SCD; safety, efficacy, mechanism of action, advancement and
potential of GBT’s drug candidates and pipeline; and working on new
targets and discovering, developing and delivering treatments, to
be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act, and GBT makes this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect GBT’s current
views about its plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to the company and on assumptions the company has made. GBT can
give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved, and, furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond GBT’s control, including, without
limitation, risks and uncertainties relating to the COVID-19
pandemic, including the extent and duration of the impact on GBT’s
business, including commercialization activities, regulatory
efforts, research and development, corporate development activities
and operating results, which will depend on future developments
that are highly uncertain and cannot be accurately predicted, such
as the ultimate duration of the pandemic, travel restrictions,
quarantines, social distancing and business closure requirements in
the U.S. and in other countries, and the effectiveness of actions
taken globally to contain and treat the disease; the risks that GBT
is continuing to establish its commercialization capabilities and
may not be able to successfully commercialize Oxbryta; risks
associated with GBT’s dependence on third parties for research,
development, manufacture, distribution and commercialization
activities; government and third-party payer actions, including
those relating to reimbursement and pricing; risks and
uncertainties relating to competitive treatments and other changes
that may limit demand for Oxbryta; the risks regulatory authorities
may require additional studies or data to support continued
commercialization of Oxbryta; the risks that drug-related adverse
events may be observed during commercialization or clinical
development; data and results may not meet regulatory requirements
or otherwise be sufficient for further development, regulatory
review or approval; compliance with obligations under the Pharmakon
loan; and the timing and progress of activities under GBT’s
collaboration, license and distribution agreements; along with
those risks set forth in GBT’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2021, and in GBT’s most recent
Quarterly Report on Form 10-Q filed with the U.S. Securities and
Exchange Commission, as well as discussions of potential risks,
uncertainties and other important factors in GBT’s subsequent
filings with the U.S. Securities and Exchange Commission. Except as
required by law, GBT assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
References
- Centers for Disease Control and
Prevention website. Sickle Cell Disease Research.
https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-understanding-sickle-cell-disease.html.
Accessed February 23, 2022.
- European Medicines Agency.
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125
Accessed February 23, 2022.
- Centers for Disease Control and
Prevention website. Sickle Cell Disease (SCD).
https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed February
23, 2022.
- National Heart, Lung, and Blood
Institute website. Sickle Cell Disease.
https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease.
Accessed February 23, 2022.
- Kato GJ, et al. Nat Rev Dis Primers.
2018;4:18010.
- Rees DC, et al. Lancet.
2010;376(9757):2018-2031.
- Kato GJ, et al. J Clin Invest.
2017;127(3):750-760.
- Caboot JB, et al. Paediatr Respir
Rev. 2014;15(1):17-23.
- Kanter J, et al. Blood Rev. 2013
Nov;27(6):279-87.
- Symphony Health Claims Data, May
2021.
Contact:Steven
Immergut (media)+1 650-410-3258simmergut@gbt.com
Courtney Roberts (investors)+1
650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2024 to May 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From May 2023 to May 2024